Genomic diversity of colorectal cancer

Changing landscape and emerging targets

Daniel Ahn, Kristen K. Ciombor, Sameh Mikhail, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Improvements in screening and preventive measures have led to an increased detection of early stage colorectal cancers (CRC) where patients undergo treatment with a curative intent. Despite these efforts, a high proportion of patients are diagnosed with advanced stage disease that is associated with poor outcomes, as CRC remains one of the leading causes of cancer-related deaths in the world. The development of next generation sequencing and collaborative multiinstitutional efforts to characterize the cancer genome has afforded us with a comprehensive assessment of the genomic makeup present in CRC. This knowledge has translated into understanding the prognostic role of various tumor somatic variants in this disease. Additionally, the awareness of the genomic alterations present in CRC has resulted in an improvement in patient outcomes, largely due to better selection of personalized therapies based on an individual's tumor genomic makeup. The benefit of various treatments is often limited, where recent studies assessing the genomic diversity in CRC have identified the development of secondary tumor somatic variants that likely contribute to acquired treatment resistance. These studies have begun to alter the landscape of treatment for CRC that include investigating novel targeted therapies, assessing the role of immunotherapy and prospective, dynamic assessment of changes in tumor genomic alterations that occur during the treatment of CRC.

Original languageEnglish (US)
Pages (from-to)5668-5677
Number of pages10
JournalWorld Journal of Gastroenterology
Volume22
Issue number25
DOIs
StatePublished - Jul 7 2016

Fingerprint

Colorectal Neoplasms
Neoplasms
Therapeutics
Immunotherapy
Genome

Keywords

  • BRAF mutation
  • Colorectal cancer
  • Genomic diversity
  • KRAS mutation
  • Tumor DNA

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Genomic diversity of colorectal cancer : Changing landscape and emerging targets. / Ahn, Daniel; Ciombor, Kristen K.; Mikhail, Sameh; Bekaii-Saab, Tanios.

In: World Journal of Gastroenterology, Vol. 22, No. 25, 07.07.2016, p. 5668-5677.

Research output: Contribution to journalReview article

@article{80d1b814cc7746f89b49ddd752d1a3f1,
title = "Genomic diversity of colorectal cancer: Changing landscape and emerging targets",
abstract = "Improvements in screening and preventive measures have led to an increased detection of early stage colorectal cancers (CRC) where patients undergo treatment with a curative intent. Despite these efforts, a high proportion of patients are diagnosed with advanced stage disease that is associated with poor outcomes, as CRC remains one of the leading causes of cancer-related deaths in the world. The development of next generation sequencing and collaborative multiinstitutional efforts to characterize the cancer genome has afforded us with a comprehensive assessment of the genomic makeup present in CRC. This knowledge has translated into understanding the prognostic role of various tumor somatic variants in this disease. Additionally, the awareness of the genomic alterations present in CRC has resulted in an improvement in patient outcomes, largely due to better selection of personalized therapies based on an individual's tumor genomic makeup. The benefit of various treatments is often limited, where recent studies assessing the genomic diversity in CRC have identified the development of secondary tumor somatic variants that likely contribute to acquired treatment resistance. These studies have begun to alter the landscape of treatment for CRC that include investigating novel targeted therapies, assessing the role of immunotherapy and prospective, dynamic assessment of changes in tumor genomic alterations that occur during the treatment of CRC.",
keywords = "BRAF mutation, Colorectal cancer, Genomic diversity, KRAS mutation, Tumor DNA",
author = "Daniel Ahn and Ciombor, {Kristen K.} and Sameh Mikhail and Tanios Bekaii-Saab",
year = "2016",
month = "7",
day = "7",
doi = "10.3748/wjg.v22.i25.5668",
language = "English (US)",
volume = "22",
pages = "5668--5677",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "25",

}

TY - JOUR

T1 - Genomic diversity of colorectal cancer

T2 - Changing landscape and emerging targets

AU - Ahn, Daniel

AU - Ciombor, Kristen K.

AU - Mikhail, Sameh

AU - Bekaii-Saab, Tanios

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Improvements in screening and preventive measures have led to an increased detection of early stage colorectal cancers (CRC) where patients undergo treatment with a curative intent. Despite these efforts, a high proportion of patients are diagnosed with advanced stage disease that is associated with poor outcomes, as CRC remains one of the leading causes of cancer-related deaths in the world. The development of next generation sequencing and collaborative multiinstitutional efforts to characterize the cancer genome has afforded us with a comprehensive assessment of the genomic makeup present in CRC. This knowledge has translated into understanding the prognostic role of various tumor somatic variants in this disease. Additionally, the awareness of the genomic alterations present in CRC has resulted in an improvement in patient outcomes, largely due to better selection of personalized therapies based on an individual's tumor genomic makeup. The benefit of various treatments is often limited, where recent studies assessing the genomic diversity in CRC have identified the development of secondary tumor somatic variants that likely contribute to acquired treatment resistance. These studies have begun to alter the landscape of treatment for CRC that include investigating novel targeted therapies, assessing the role of immunotherapy and prospective, dynamic assessment of changes in tumor genomic alterations that occur during the treatment of CRC.

AB - Improvements in screening and preventive measures have led to an increased detection of early stage colorectal cancers (CRC) where patients undergo treatment with a curative intent. Despite these efforts, a high proportion of patients are diagnosed with advanced stage disease that is associated with poor outcomes, as CRC remains one of the leading causes of cancer-related deaths in the world. The development of next generation sequencing and collaborative multiinstitutional efforts to characterize the cancer genome has afforded us with a comprehensive assessment of the genomic makeup present in CRC. This knowledge has translated into understanding the prognostic role of various tumor somatic variants in this disease. Additionally, the awareness of the genomic alterations present in CRC has resulted in an improvement in patient outcomes, largely due to better selection of personalized therapies based on an individual's tumor genomic makeup. The benefit of various treatments is often limited, where recent studies assessing the genomic diversity in CRC have identified the development of secondary tumor somatic variants that likely contribute to acquired treatment resistance. These studies have begun to alter the landscape of treatment for CRC that include investigating novel targeted therapies, assessing the role of immunotherapy and prospective, dynamic assessment of changes in tumor genomic alterations that occur during the treatment of CRC.

KW - BRAF mutation

KW - Colorectal cancer

KW - Genomic diversity

KW - KRAS mutation

KW - Tumor DNA

UR - http://www.scopus.com/inward/record.url?scp=84977644917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977644917&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i25.5668

DO - 10.3748/wjg.v22.i25.5668

M3 - Review article

VL - 22

SP - 5668

EP - 5677

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 25

ER -